Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 290Glioblastoma 260Glioma 202Neuroblastoma 88Neoplasms 62Astrocytoma 56Central Nervous System Neoplasms 54Medulloblastoma 48Breast Neoplasms 44Melanoma 40Sarcoma 39Meningioma 39Neurofibromatosis 1 38Carcinoma, Non-Small-Cell Lung 38Lung Neoplasms 37Ependymoma 36Osteosarcoma 31Rhabdomyosarcoma 30Neoplasm Metastasis 28Sarcoma, Ewing 27Rhabdoid Tumor 27Diffuse Intrinsic Pontine Glioma 27Recurrence 26Oligodendroglioma 23Gliosarcoma 22Wilms Tumor 21Pancreatic Neoplasms 21Pheochromocytoma 20Hepatoblastoma 20Neurofibroma, Plexiform 19

Interventions

Panitumumab 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × CNS × 90 days × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡